Is screening for glaucoma necessary? A policy guide and analysis

Journal of Ophthalmic and Vision Research

Volumn 9, Issue 1, 2014, Pages 3-6

  Mohammadi, Seyed Farzad ^a,b   Saeedi Anari, Ghasem ^b   Alinia, Cyrus ^b   Ashrafi, Elham ^b   Daneshvar, Ramin ^c   Sommer, Alfred ^d  

^a MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899696824     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
2. Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, Sintonen H, Suoranta L, Kovanen N, et al. Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand 2007;85:508-518.
3. Pakravan M, Yazdani S, Javadi MA, Amini H, Behroozi Z, Ziaei H, et al. A population-based survey of the prevalence and types of glaucoma in central Iran: the Yazd Eye study. Ophthalmology 2013;120:1977-1984.
4. Programme areas: Prevention of Ophthalmic Diseases. WHO Country Office in Islamic Republic of Iran. http://www.emro.who.int/ iran/ProgrammeAreas-OphthalmicDiseases.htm. Accessed June 17, 2011.
5. Amini H, Javadi MA, Yazdani S, Pakravan M, Karimian F, Rezaei A, et al. The prevalence of glaucoma in Tehran, Iran. J Ophthalmic Vis Res 2007;2:93-100.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279.
7. Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol 1991;109:77-83.
8. Tuulonen A, Sintonen H. Health economics, cost-effectiveness, and glaucoma care. In: Grehn F, Stamper R (eds). Essentials of ophthalmology, glaucoma. 1st ed. Heidelberg: Springer; 2006: 123-124.
9. Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci 2011;88:155-163.
10. Burr JM, Mowatt G, Hernández R, Siddiqui MA, Cook J, Lourenco T, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-190.
11. Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009;116:823-832.
12. Gottlieb LK, Schwartz B, Pauker SG. Glaucoma screening. A cost-effectiveness analysis. Surv Ophthalmol 1983;28:206-226.
13. Tuck MW, Crick RP. The cost-effectiveness of various modes of screening for primary open angle glaucoma. Ophthalmic Epidemiol 1997;4:3-17.
14. Mohammadi SF, Mirhadi S, Z. Mehrjardi H, Fotouhi A, Taba Taba Vakili S, Majdi M, et al. An algorithm for glaucoma screening in clinical settings and its preliminary performance profile. J Ophthalmic Vis Res 2013;8:314-320.
15. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010;27:249-256.
16. Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J. The clinical effectiveness and costeffectiveness of screening programs for amblyopia and strabismus in children up to the age of 4-5 years; a systematic review and economic evaluation. Health Technol Assess 2008;12: iii, xi-194.
17. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are costeffectiveness thresholds expected to emerge? Value Health 2004;7:518-528.
18. Bureau of WHO-CHOICE, Department of Health Systems and Innovation (HIS), WHO (Switzerland). http://www.who.int/choice/costs/CER_levels/en. Accessed March 8, 2014.
19. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making Choice in Health: WHO Guide to Cost Effectiveness Analysis. 1st ed. Geneva: World Health Organisation; 2003.
20. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006;47:4254-4261.
21. He M, Foster PJ, Johnson GJ, Khaw PT. Angleclosure glaucoma in East Asian and European people. Different diseases? Eye (Lond) 2006;20:3-12.
22. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73.
23. Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1640-1645.
24. Thomas R, Parikh R, Paul P, Muliyil J. Populationbased screening versus case detection. Indian J Ophthalmol 2002;50:233-237.
25. Wong EY, Keeffe JE, Rait JL, Vu HT, Le A, McCarty PhD C, et al. Detection of undiagnosed glaucoma by eye health professionals. Ophthalmology 2004;111:1508-1514.
26. Levi L, Schwartz B. Glaucoma screening in the health care setting. Surv Ophthalmol 1983;28:164-174.